Art. 16 Regulation (EU) 2016/161

Verifications to be performed before removing or replacing the safety features

In forcesince 2 Oct 2015cited 4×
1.

Before removing or covering, either fully or partially, the safety features in accordance with Article 47a of Directive 2001/83/EC, the manufacturer shall verify the following:

(a)

the integrity of the anti-tampering device;

(b)

the authenticity of the unique identifier and decommission it if replaced.

2.

Manufacturers holding both a manufacturing authorisation according to Article 40 of Directive 2001/83/EC and an authorisation to manufacture or import investigational medicinal products to the Union as referred to in Article 61 of Regulation (EU) No 536/2014 of the European Parliament and of the Council [Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC (OJ L 158, 27.5.2014, p. 1).] shall verify the safety features and decommission the unique identifier on a pack of medicinal product before repackaging or re-labelling it for the purpose of using it as authorised investigational medicinal product or authorised auxiliary medicinal product.

  • Opinion of Advocate General Szpunar delivered on 13 January 2022. Novartis Pharma GmbH v Abacus Medicine A/S.Decision

    It may therefore be the case that the parallel trader is required to replace the unique identifier of a medicinal product [In accordance with Article 47a of Directive 2001/83 and Articles 16 and 17 of Delegated Regulation 2016/161.] or to …

    13 Jan 2022 · 62020CC0147

  • Judgment of the Court (Fifth Chamber) of 17 November 2022. Merck Sharp & Dohme BV and Others v Abacus Medicine A/S and Others.Decision

    Article 16(1) of that delegated regulation provides: ‘Before removing or covering, either fully or partially, the safety features in accordance with Article 47a of Directive [2001/83], the manufacturer shall verify the following: the …

    17 Nov 2022 · 62020CJ0224

  • Judgment of the Court (Fifth Chamber) of 17 November 2022. Bayer Intellectual Property GmbH v kohlpharma GmbH.Decision

    Under Article 16(1) of that delegated regulation: ‘Before removing or covering, either fully or partially, the safety features in accordance with Article 47a of Directive [2001/83], the manufacturer shall verify the following: the …

    17 Nov 2022 · 62020CJ0204

  • Judgment of the Court (Fifth Chamber) of 17 November 2022. Novartis Pharma GmbH v Abacus Medicine A/S.Decision

    Under Article 16(1) of that delegated regulation: ‘Before removing or covering, either fully or partially, the safety features in accordance with Article 47a of Directive [2001/83], the manufacturer shall verify the following: the …

    17 Nov 2022 · 62020CJ0147